Document:

<PAGE>

                                                                   Exhibit 10.38

                        FOUNDER STOCK PURCHASE AGREEMENT
                        --------------------------------

          THIS AGREEMENT is made this 12th day of April, 2001, by and between
Spine Wave, Inc., a Delaware corporation (the "Company"), and Protein Polymer
Technologies, Inc. ("Purchaser").

          NOW THEREFORE, IT IS HEREBY AGREED:

          1.   Sale of Stock. Subject to the terms hereof, the Company shall
               -------------
sell to Purchaser and Purchaser shall purchase from the Company One Million
(1,000,000) shares of common stock of the Company (the "Stock"). The sale and
purchase shall occur at the offices of the Company on the date set forth above
or at such other place and time as the parties may agree (the "Closing").

          2.   Consideration. In exchange for and as full consideration for the
               -------------
Stock, the Purchaser shall enter into that certain License Agreement with the
Company attached hereto as Exhibit A (the "License Agreement") pursuant to which
                           ---------
Purchaser grants to the Company exclusive rights to certain of Purchaser's
intellectual property solely for use in the Field (as defined in the License
Agreement). In addition, Purchaser shall deliver two (2) duly executed blank
Assignments Separate from Certificate in the form attached hereto as Exhibit C,
                                                                     ---------
which Assignments Separate from Certificate shall only be used in connection
with the exercise of the Company's Repurchase Option as set forth in Section 4
below. The Company and the Purchaser agree that the fair market value of each
share of Stock as of the date of this Agreement equals ** per share (the
"Purchase Price").

          3.   Issuance of Stock. Upon the execution and delivery of the License
               -----------------
Agreement by the Purchaser, the Company shall issue a duly executed certificate
evidencing the Stock in the name of Purchaser and provide Purchaser with a copy
of such certificate. The original of such certificate shall be held in escrow by
the Company until the expiration of the Repurchase Option (as defined below);
provided however, upon Purchaser's request, Company shall release to Purchaser a
certificate representing that number of shares of the Stock which, as of the
date of such request, are no longer subject to the Repurchase Option set forth
in Section 4 below.

          4.   Repurchase Option. The Stock shall be subject to a right (but not
               -----------------
an obligation) of repurchase by the Company (the "Repurchase Option"). The
Company shall have the right to purchase Unvested Shares (as defined below) from
the Purchaser at the Purchase Price on or after termination of the License
Agreement (such termination to be pursuant to the terms set forth therein).

               a. This Repurchase Option shall lapse in accordance with the
schedule attached hereto as Exhibit B (the "Schedule") which sets forth the
                            ---------
amount of Stock which may be repurchased under the Repurchase Option ("Unvested
Shares") and the corresponding contingencies for repurchase. The Repurchase
Option shall terminate and cease to be exercisable with respect to any and all
Unvested Shares upon the earlier of (i) the date that is seven years from the
date hereof; (ii) the date upon which the **; (iii) the consummation of a

**Material is confidential and has been omitted and filed separately with the
Securities and Exchange Commission.

<PAGE>

merger, consolidation or other reorganization of the Company ("Merger") in which
(1) securities representing more than 50% of the total combined voting power of
the voting securities of the successor business entity are not immediately
thereafter beneficially owned directly or indirectly and in substantially the
same proportion by the persons who beneficially owned the Company's outstanding
voting securities immediately prior to such Merger, or (2) the consideration to
the Company's stockholders for the Merger is not solely voting securities, or
(3) at least 50% of the senior executive officers of Company immediately prior
to the Merger do not continue as senior executive officers of the successor
business entity; (iv) the completion of a sale, transfer or other disposition of
all or substantially all of the Company's assets; or (v) the consummation of the
Company's sale of its common stock in a public offering pursuant to a
registration statement under the Securities Act of 1933, as amended (the "Act").

               b.   The Repurchase Option shall be exercised by written notice
signed by the President or Treasurer of the Company and delivered as provided in
subparagraph 10(b) hereof. The Company may pay for the shares of Stock it has
elected to repurchase by delivery of a cashier's check or by wire transfer of
immediately available funds in an aggregate amount equal to the Purchase Price
multiplied by the number of shares of Stock being repurchased.

               c.   Adjustments to Stock. If, from time to time during the term
                    --------------------
of the Repurchase Option, there is any change affecting the Company's
outstanding common stock as a class that is effected without the receipt of
consideration by the Company (through merger, consolidation, reorganization,
reincorporation, stock dividend, dividend in property other than cash, stock
split, liquidating, dividend, combination of shares, change in corporation
structure or other transaction not involving the receipt of consideration by the
Company), then any and all new, substituted or additional securities or other
property to which Purchaser is entitled by reason of Purchaser's ownership of
Stock shall be immediately subject to the Repurchase Option and be included in
the word "Stock" for all purposes of the Repurchase Option with the same force
and effect as the shares of the Stock presently subject to the Repurchase
Option, but only to the extent the Stock is, at the time, covered by such
Repurchase Option. While the aggregate Purchase Price shall remain the same
after each such event, the Purchase Price per share of Stock upon exercise of
the Repurchase Option shall be appropriately adjusted.

          5.   Right of First Refusal. Stock subject to the Repurchase Option
               ----------------------
may not be transferred, except for transfers by operation of law or other
involuntary transfer. Before any shares of Stock registered in the name of
Purchaser and not subject to the Repurchase Option may be sold or transferred
(excluding transfer by operation of law or other involuntary transfer) such
shares shall first be offered to the Company in the following manner:

               a.   The Purchaser or its transferee shall deliver a notice
pursuant to subparagraph 10(b) ("Notice") to the principal business office of
the Company stating (i) the bona fide intention to sell or transfer such shares,
(ii) the number of such shares of Stock to be sold or transferred, (iii) the
price and other terms, if any, for which Purchaser or its transferee proposes to
sell or transfer such shares of Stock, and (iv) the name and address of the
proposed purchaser or transferee and that such purchaser or transferee is
committed to acquire the stated number of shares on the stated price and terms.

                                       2

<PAGE>

               b. The Company shall have the right at any time within twenty
(20) days of receipt of the Notice to purchase all of the shares to which the
Notice refers at the price per share specified in the Notice, or if no price is
specified therein, at the fair market value thereof as determined by the Board
of Directors in good faith. Said right shall be exercised by written notice
signed by the President or any Vice President of the Company and delivered as
provided in subparagraph 10(b) hereof, which notice shall specify the time,
place and date for settlement of such purchase.

               c. In the event the Company does not, for any reason, exercise
its right pursuant hereto, the Company may assign such right, provided such
right shall not extend beyond such twenty (20) day period. If exercised by the
assignee pursuant hereto, the right to purchase shall be exercised by written
notice signed by the exercising assignee and delivered as provided in
subparagraph 10(b) hereof, which notice shall specify the time, place and date
for settlement of such purchase. Purchaser shall sell the shares to the Company
or such assignees within thirty (30) days after the date of the Notice.

               d. If all of the shares to which the Notice refers are not
purchased, as provided in subparagraphs 5(b) or 5(c) above, the Purchaser may
sell such shares to the person named in the Notice at the price and terms
specified in the Notice, provided that such sale or transfer is consummated
within seventy five (75) days of the date of the Notice to the Company, and
provided further that any such sale is in accordance with all the terms and
conditions hereof. If Purchaser does not consummate the sale or transfer within
such seventy five (75) day period, the right provided hereby shall be deemed to
be revived with respect to such shares and no sale or transfer shall be effected
without first offering the shares in accordance herewith.

               e. Notwithstanding the above, neither the Company nor the
assignees of the Company shall have any right of first refusal under this
Section 5 at any time subsequent to the following: i) the closing of a bona
fide, firm commitment underwritten public offering of the common stock of the
Company pursuant to a Registration Statement declared effective under the Act,
or ii) the first date on which the Stock is held of record by more than five
hundred (500) persons. In addition, the Company's right of first refusal under
this Section 5 shall not apply to the proposed sale or transfer by Purchaser of
stock subject to this Agreement as part of the sale of all or substantially all
of Purchaser's assets ("Sale of Assets") except in the event that the Sale of
Assets is to a direct competitor of the Company or to such other entity which
directly or indirectly controls a direct competitor of the Company and provided
that in such circumstance, the time period set forth in subparagraph 5(d) above
shall be 180 days.

          6.   "Market Stand-Off" Agreement. Purchaser hereby agrees that,
                ---------------------------
during the period specified by the Company (such period not to exceed one
hundred eighty (180) days in the case of an initial public offering, and ninety
(90) days for all subsequent offerings) and the underwriter or underwriters of
common stock (or other securities) of the Company following the effective date
of a registration statement of the Company filed under the Act, Purchaser shall
not, to the extent requested by the Company and such underwriter, and without
the prior written consent of the managing underwriter of such offering, directly
or indirectly, sell, offer or contract to sell (including, without limitation,
any short sale), grant any option to purchase or otherwise

                                       3

<PAGE>

transfer or dispose of (other than to donees who agree to be similarly bound)
any securities of the Company at any time during such period except common stock
included in such registration, provided, however, that all officers, directors,
founders (to the extent such founder is employed by the Company at such time)
and beneficial holders of 5% or more of the Company holding securities of the
Company enter into similar agreements.

          In order to enforce the foregoing covenant, the Company may impose
stop-transfer instructions with respect to common stock held by Purchaser until
the end of such period.

          7.   Representations and Warranties of Purchaser.
               -------------------------------------------

               a.   Due Authorization. Purchaser hereby represents and warrants
                    -----------------
to Company that it is duly authorized and empowered to enter into and perform
this Agreement; and the execution and performance of this Agreement by Purchaser
does not and will not conflict with or violate any contract, agreement,
indenture, mortgage, instrument, writ, judgment, or order of any court, arbiter
or governmental or quasi-governmental body to which Purchaser is a party or by
which Purchaser is bound.

               b.   Investment Intent. This Agreement is made with Purchaser in
                    -----------------
reliance upon its representation to the Company, which by Purchaser's acceptance
hereof confirms, that the Stock has been acquired by Purchaser for investment
for an indefinite period for Purchaser's own account, not as a nominee or agent,
and not with a view to the sale or distribution of any part thereof, and that
Purchaser has no present intention of selling, granting participation in, or
otherwise distributing the same. By executing this Agreement, Purchaser further
represents that Purchaser does not have any contract, undertaking, agreement or
arrangement with any person to sell, transfer, or grant participations, to such
person or to any third person, with respect to any of the Stock.

               c.   Restricted Securities. Purchaser understands that the Stock
                    ----------------------
has not been registered under the Act, on the ground that the sale provided for
in this Agreement is exempt from the registration requirements of the Act, and
that the Company's reliance on such exemption is predicated on Purchaser's
representations set forth herein.

          Purchaser understands that if the Company does not register with the
Securities and Exchange Commission pursuant to Section 12 or 15 of the
Securities Exchange Act of 1934, as amended, or if a registration statement
covering the Stock (or a filing pursuant to the exemption from registration
under Regulation A of the Act) under the Act is not in effect when Purchaser
desires to sell the Stock, Purchaser may be required to hold the Stock for an
indeterminate period. The Purchaser also acknowledges that Purchaser understands
that any sale of the Stock that might be made Purchaser in reliance upon Rule
144 under the Act may be made only in limited amounts in accordance with the
terms and conditions of that rule and that Purchaser may not be able to sell the
Stock at the time or in the amount Purchaser so desires. Purchaser is familiar
with Rule 144 and understands that the Stock constitutes "restricted securities"
within the meaning of that Rule.

               d.   Investment Experience. In connection with the investment
                    ---------------------
representations made herein Purchaser represents that Purchaser is either an
"Accredited

                                        4

<PAGE>

Investor", as that term is defined in Rule 501 of Regulation D promulgated under
the Act, or is able to fend for itself in the transactions contemplated by this
Agreement, has such knowledge and experience in financial and business matters
as to be capable of evaluating the merits and risks of its investment, has the
ability to bear the economic risks of its investment and has been furnished with
and has had access to such information as Purchaser has requested and deems
appropriate to its investment decision.

               e.   Limitations  on  Disposition.  Purchaser agrees that in no
                    ----------------------------
event will Purchaser make a disposition of any of the Stock, unless and until
(i) Purchaser shall have notified the Company of the proposed disposition, and
(ii) Purchaser shall have furnished the Company with an opinion of counsel
satisfactory to the Company to the effect that such disposition will not require
registration of such Stock under the Act or that appropriate action necessary
for compliance with the Act has been taken, or (iii) the Company shall have
waived, expressly and in writing, its rights under clauses (i) and (ii) of this
subparagraph. In addition, prior to any disposition of any of the Stock, the
Company shall require the transferee or assignee to provide in writing
investment representations and such transferee's or assignee's agreement to be
bound by the right of first refusal and market stand-off provisions hereof in a
form acceptable to the Company.

               The Company shall not be required (I) to transfer on its books
any shares of Stock of the Company which shall have been sold or transferred in
violation of any of the provisions set forth in this Agreement, or (II) to treat
as owner of such shares or to accord the right to vote as such owner or to pay
dividends to any transferee to whom such shares shall have been so transferred.
Purchaser shall, during the term of this Agreement, exercise all rights and
privileges of a stockholder of the Company with respect to the Stock after the
issuance, and prior to the repurchase, thereof.

               f.   Legends. All certificates representing any shares of Stock
                    -------
of the Company subject to the provisions of this Agreement shall have endorsed
thereon the following legends:

               (i)  "THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"). THESE
SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION
OR RESALE, AND THEY MAY NOT BE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION
STATEMENT FOR SUCH SHARES UNDER THE ACT OR PURSUANT TO RULE 144 UNDER THE ACT OR
AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT
REQUIRED UNDER THE ACT."

               (ii) "THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT
TO THE TERMS AND CONDITIONS OF A CERTAIN FOUNDER STOCK PURCHASE AGREEMENT
BETWEEN THE COMPANY AND THE HOLDER HEREOF WHICH INCLUDES A MARKET STAND-OFF
AGREEMENT, A RIGHT OF REPURCHASE AND A RIGHT OF FIRST REFUSAL ON THE SALE OF THE
SECURITIES. THESE SECURITIES MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, ENCUMBERED,
OR IN ANY MANNER DISPOSED OF EXCEPT IN CONFORMITY WITH

                                        5

<PAGE>

THE TERMS OF SUCH AGREEMENT. COPIES OF THE AGREEMENT MAY BE OBTAINED UPON
WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY."

               (iii) Any legend required to be placed thereon by applicable
state laws.

          8.   Conditions Precedent to Purchaser's Obligations. Pursuant to the
               -----------------------------------------------
terms of that certain Convertible Promissory Note Purchase Agreement of even
date herewith (the "Note Purchase Agreement"), on the date of Closing, Windamere
II LLC ("Investor") shall have purchased and Company shall have issued to
Investor that certain Convertible Promissory Note in aggregate principal amount
of ** (the "Convertible Note"). Pursuant to the terms of the Note Purchase
Agreement, Investor shall have the right to purchase, in ** increments, up to **
aggregate principal amount of additional convertible promissory notes on the
same terms as the Convertible Note.

          9.   Representations and Warranties of Company.
               -----------------------------------------

               a. As of the date of Closing, the authorized capital stock of the
Company consists of 4,000,000 shares of common stock, $.001 par value per share,
(the "Common Stock").

               b. As of the date of Closing, the Company has reserved 1,500,000
shares of Common Stock for issuance pursuant to the Company's 2001 Stock
Option/Stock Issuance Plan.

               c. Immediately following the Closing, the Company shall have
issued and outstanding 2,950,000 shares of Common Stock.

               d. Company hereby represents and warrants to Purchaser that it is
duly authorized and empowered to enter into and perform this Agreement; and the
execution and performance of this Agreement by the Company does not and will not
conflict with or violate any contract, agreement, indenture, mortgage,
instrument, writ, judgment, or order of any court, arbiter or governmental or
quasi-governmental body to which the Company is a party or by which the Company
is bound.

          10.  Miscellaneous.
               -------------

               a. Further Instruments and Actions. The parties agree to execute
                  -------------------------------
such further instruments and to take such further action as may reasonably be
necessary to carry out the intent of this Agreement.

               b. Notices. All notices required or permitted hereunder shall be
                  -------
in writing and shall be deemed effectively given: (i) upon personal delivery to
the party to be notified, (ii) when sent by confirmed facsimile transmission if
sent during normal business hours of the recipient; if not, then on the next
business day, or (iii) for domestic addresses one (1) business day after deposit
with a nationally recognized overnight courier, specifying next day delivery,
with written verification of receipt and for international addresses three (3)
business days after deposit with a nationally recognized overnight courier,
specifying next day delivery,

**Material is confidential and has been omitted and filed separately with the
Securities and Exchange Commission.

                                       6

<PAGE>

with written verification of receipt. All communications shall be sent to the
party to be notified at the address as set forth on the signature pages hereof
or at such other address as such party may designate by ten (10) days advance
written notice to the other parties hereto.

               c.  Governing Law, Assignment and Enforcement. This Agreement is
                   -----------------------------------------
governed by the internal law of California and shall inure to the benefit of the
successors and assigns of the Company and, subject to the restrictions on
transfer herein set forth, be binding upon Purchaser, its successors and
assigns. The prevailing party in any action to enforce this Agreement shall be
entitled to attorneys' fees and costs. The parties agree that damages are not an
adequate remedy for breach hereof and each party shall accordingly be entitled
to specific performance of this Agreement.

               d.  Entire Agreement; Amendments and Waivers. This Agreement and
                   ----------------------------------------
the related License Agreement, Supply and Services Agreement, Voting Agreement
and Escrow Agreement, among Purchaser and Company, and all of even date
herewith, constitute the entire agreement and understanding between the parties
with respect to the subject matter contained herein, and there are no promises,
representations, conditions, provisions or terms related thereto other than as
set forth in this Agreement and the related License Agreement, the Supply and
Services Agreement, Voting Agreement and Escrow Agreement between the Purchaser
and Company all of even date herewith. This Agreement may only be amended with
the written consent of the parties hereto, or their successors or assigns, and
no oral waiver or amendment shall be effective under any circumstances
whatsoever.

               e.  Cooperation. Purchaser agrees to cooperate affirmatively with
                   -----------
the Company, to the extent reasonably requested by the Company, to enforce
rights and obligations pursuant to this Agreement.

          11.  California Commissioner of Corporations. THE SALE OF THE
               ---------------------------------------
SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH
THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA, AND THE ISSUANCE OF
SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION
THEREFOR PRIOR TO SUCH QUALIFICATION IS UNLAWFUL UNLESS THE SALE OF SECURITIES
IS EXEMPT FROM QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA
CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY
CONDITIONED UNLESS THE SALE IS SO EXEMPT.

                                        7

<PAGE>

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the day and year first above written.

                                   SPINE WAVE, INC.

                                   By: _________________________________________
                                       David Coats
                                       President and Chief Executive Officer

                         Address:  12230 El Camino Real, Suite 300
                                   San Diego, California 92130

                                   PURCHASER

                                   Protein Polymer Technologies, Inc.

                                   _____________________________________________
                                       J. Thomas Parmeter
                                       President and Chief Executive Officer

                         Address:  10655 Sorrento Valley Road
                                   San Diego, California 92121

              [Signature Page To Founder Stock Purchase Agreement]

<PAGE>

                                    EXHIBIT A
                                    ---------

                               [LICENSE AGREEMENT]

Filed separately under Exhibit 10.39 of the Registrant's Form 10-KSB for fiscal
year ended December 31, 2001.

<PAGE>

                                    EXHIBIT B
                                    ---------

                                VESTING SCHEDULE

**

** Material is confidential and has been omitted and filed separately with the
   Securities and Exchange Commission.

<PAGE>

                                    EXHIBIT C
                                    ---------

                      ASSIGNMENT SEPARATE FROM CERTIFICATE

          FOR VALUE RECEIVED, Protein Polymer Technologies, Inc. hereby sells,
assigns and transfers unto _____________________________, ______________________
(__) shares of the Common Stock of Spine Wave, Inc., standing in its name on the
books of said corporation represented by Certificate No.___ herewith and do
hereby irrevocably constitute and appoint __________________ attorney to
transfer said stock on the books of the within-named corporation with full power
of substitution in the premises.

Dated: _________________, _____.

                                         Protein Polymer Technologies, Inc.

                                         _______________________________________
                                         By:
                                         Its:

          This Assignment Separate from Certificate was executed in conjunction
with the terms of a Founder Stock Purchase Agreement between the above assignor
and Spine Wave, Inc. dated April __, 2001.<PAGE>

                                                                   Exhibit 10.39

                                LICENSE AGREEMENT

     This Agreement entered into and effective as of April 12, 2001 (the
"Effective Date") is between PROTEIN POLYMER TECHNOLOGIES, INC., a Delaware
corporation (hereinafter referred to as "PPTI"), and SPINE WAVE, INC., a
Delaware corporation (hereinafter referred to as "Company").

                              W I T N E S S E T H:

     WHEREAS, PPTI desires to grant to the Company, and the Company desires to
receive, a license with respect to certain of PPTI's intellectual property
rights;

     WHEREAS, the parties are entering into a Founder Stock Purchase Agreement
of even date herewith (the "Purchase Agreement"), pursuant to which the Company
will issue to PPTI 1,000,000 shares of the Company's common stock, as partial
consideration for the rights granted under this Agreement;

     NOW, THEREFORE, in consideration of the mutual covenants herein contained,
PPTI and Company agree as follows:

1.   DEFINITIONS.
     -----------

     In this Agreement (including the recitals) the following expressions shall
have the following meanings unless the context otherwise requires:

          "Affiliate" shall mean, in relation to either party, (a) any
     corporation, partnership, limited liability company, or other entity
     ("Entity") in which the relevant party directly or indirectly holds 50% or
     more of the voting interests, (b) any Entity which holds directly or
     indirectly 50% or more of the voting stock or shares of the relevant party,
     (c) any other Entity in which 50% or more of the voting interests is
     directly or indirectly held by any Entity described in clause (b), or (d)
     any Entity in which the relevant party directly or indirectly holds less
     than 50% of the voting interests but has management control of such Entity
     in that it has the ability to appoint or remove the majority of the
     directors or managers of such Entity. For the purpose of this definition,
     PPTI shall not be an Affiliate of Company, and Company shall not be an
     Affiliate of PPTI.

          "Calendar Quarter" shall mean the usual and customary calendar
     quarters, the first quarter being the months of January, February and
     March, the second quarter being the months of April, May and June, the
     third quarter being the months of July, August and September, and the
     fourth quarter being the months of October, November and December.

          "Copyright" shall mean all copyright and rights in the nature of
     copyright now or subsequently owned or controlled by PPTI or its
     SubsidIiaries at any time prior to or during the term of this Agreement
     relating to or embodying any part of the Know-How,

<PAGE>

     including without limitation any materials consisting of or containing
     software or databases.

          "Cost of Goods Sold" shall mean, for any applicable period, Company's
     cost of goods for Products sold determined in accordance with generally
     accepted accounting principles, consistently applied.

          "Escrow Materials" shall mean (i) the "Gene Construction Technology
     Materials" described on Schedule 1 of the Escrow Agreement; (ii) the
     "Biomechanical Standard Formulation(s) Escrow Materials" described on
     Schedule 2 of the Escrow Agreement; (iii) the "Commercial Production Escrow
     Materials" described on Schedule 3 of the Escrow Agreement; and (iv) the
     "Protein Polymer Design and Supply Escrow Materials" described on Schedule
     4 of the Escrow Agreement.

          "Field" shall mean human or veterinary applications involving
     treatment, repair and/or diagnosis of conditions of the spine; provided
     that with respect to any Intellectual Property covering ** the Field shall
     mean all orthopaedic applications, including treatment or diagnosis of
     deformities of the musculoskeletal system, which includes all of the bones
     and cartilages of the body and associated muscle attachments.

          "Gene Construction Technology" shall mean the methods used to create
     DNA encoding protein polymers, including without limitation, the methods
     described in US Patents 5,641,648 and 5,830,713.

          "Gross Margin" shall mean, for a Product, the invoiced price of such
     Product upon the sale by Company or any Affiliate of the Company to another
     entity, less the Cost of Goods Sold of such Product for the applicable
     accounting period.

          "IDE Approval" shall mean approval of an investigational device
     exemption application filed with the United States Food and Drug
     Administration, or the equivalent regulatory approval in Japan, Canada or
     any western European country.

          "Intellectual Property" shall mean Patents, Know-How (including
     without limitation, the Escrow Materials) and Copyright.

          "Know-How" shall mean all trade secrets, inventions, methods,
     processes, negative know-how, techniques, products, designs, cultures,
     other biological materials and other materials and compositions,
     information, data or experience whether patentable or not, useful in the
     Field that are (i) owned or controlled by PPTI or its Subsidiaries as of
     the Effective Date or (ii) developed, acquired or that otherwise become
     controlled by PPTI or its Subsidiaries at any time during the term of this
     Agreement, including without limitation, processes, techniques, methods,
     operating instructions, machinery designs, raw material or product
     specifications, drawings, blue prints, laboratory books, notes, records and
     any other technical and commercial information relating to research,
     design, development, manufacture, assembly, use or sale of the Products in
     the Field.

** Material is confidential and has been omitted and filed separately with the
Securities and Exchange Commission.

                                       2

<PAGE>

          "Marketing Period" shall mean any consecutive 12-month period
     beginning after the first month during which Company first sells a Product
     to independent third parties on a commercial basis.

          "Net Sales" shall mean the ** of Products sold by Company to any other
     entities, less **.

          "Patent(s)" shall mean:

               (a) any and all patents and applications for patents owned or
          controlled by PPTI as of the Effective Date which are useful in the
          Field including, but not limited to, those that are identified in
          Schedule A, along with any and all foreign counterparts thereof, all
          continuations, continuations-in-part, divisions and renewals thereof,
          all patent supplementary protection certificates and similar rights
          that are based on or derive priority from any of the foregoing or
          which may be granted thereon, and all reissues, re-examinations,
          extensions, patents of addition and patent of importation thereof;

               (b) any and all patent applications by PPTI or its Subsidiaries
          useful in the Field that are filed, acquired or that otherwise become
          controlled by PPTI during the term of this Agreement, all
          continuations, continuations-in-part or divisions of any such
          applications, any patents which shall issue based on such
          applications, continuations, continuations-in-part, or divisions and
          any and all patents, patent supplementary protection certificates and
          similar rights that are based upon or derive priority from any of the
          foregoing or which may be granted thereon and all reissues, renewals
          or extensions thereof or patents of addition thereto; and

               (c) all such patent applications, patents Certificates and
          rights, a Valid Claim of which would be infringed by the manufacture,
          marketing, use or sale of the Product (but for the license granted
          herein).

          "Product(s)" shall mean (i) any product in the Field which is covered
     in whole or in part by at least one Valid Claim of the Patents; and (ii)
     any product in the Field made by any process which is covered in whole or
     in part by at least one Valid Claim of Patents.

          "Royalty Term" shall mean, with respect to any Product, the period
     commencing on the Royalty Term Commencement Date and lasting until the
     expiration of all Valid Claims of Patents covering such Product either in
     the United States or in the country in which the Product is being sold.

          "Sublicense Fees" shall mean the sum of all sublicensing consideration
     received by Company from its sublicensees attributable to Company's
     sublicense of any of its rights under the License including royalties on
     Net Sales received by Company from sales of Products by such sublicensees,
     which sublicensing consideration shall exclude (i) amounts attributable to
     equity purchases of Company stock, and (ii) research and

** Material is confidential and has been omitted and filed separately with the
Securities and Exchange Commission.

                                        3

<PAGE>

     development payments (other than that portion of the amount attributable to
     research and development payments to Company which exceeds the fair market
     value of performing the related research and development activities at the
     time of such Company sublicense). Notwithstanding the foregoing, Sublicense
     Fees shall not include usual and customary payments received by Company
     pursuant to sales agreements, marketing agreements, distribution agreements
     or similar agreements between Company and any third party. For the purpose
     of clarity, Sublicense Fees shall not include any sales of Products by
     Company to any third party.

          "Sublicense Payment" shall have the meaning set forth in Article
                                                                   -------
     4.3(a).
     ------

          "Subsidiary" shall mean a corporation, limited liability company or
     partnership of which a party holds 50% or more of the voting or economic
     interest. For the purpose of this definition, Company shall not be a
     Subsidiary of PPTI.

          "Supply Agreement" shall mean that certain Supply and Services
     Agreement entered into between PPTI and Company of even date herewith.

          "Valid Claim" shall mean a claim in any unexpired Patent which has not
     been held invalid by a decision of a court or other appropriate body of
     competent jurisdiction against which there is no appeal or where any period
     for appealing against such decision has expired without an appeal having
     been validly submitted.

2.   GRANT OF LICENSE.
     ----------------

     2.1  Rights Granted.
          --------------

          (a)  Subject to the terms and conditions of this Agreement, PPTI
hereby grants to Company and Company hereby accepts from PPTI an exclusive,
worldwide, non-transferable (except in accordance with Article 21 hereof)
                                                       ----------
license (the "License"), with the right to sublicense (subject to paragraph (b)
below), to the Intellectual Property to make, have made, modify, import, use,
offer to sell, sell and have sold Products and perform and have performed
processes under the Intellectual Property, solely in the Field.

          (b)  Company may not sublicense any of its rights under the License to
Gene Construction Technology without the prior written approval of PPTI, such
approval not to be unreasonably conditioned, withheld or delayed; provided,
however, that Company may sublicense any of such rights, without such prior
written approval, (i) to any Affiliate of the Company and (ii) in connection
with a sublicense of any of its License rights with respect to a subset of the
Field, but in each case subject to Section 2.2 of this Agreement and Sections 2
and 4 of the Supply Agreement.

          (c)  PPTI hereby agrees that it shall not, without the prior written
consent of Company, use, make, have made, modify, import, use, perform, offer to
sell, sell or have sold any products, compositions or methods in the Field, or
license or transfer to any third party (including without limitation, any
Affiliate) any of such rights in the Field.

                                       4

<PAGE>

          (d)  With respect to any Intellectual Property developed or acquired
by PPTI after the Effective Date, Company agrees that the License with respect
to such after-acquired Intellectual Property shall be subject to any **.

     2.2  Right of First Offer to Manufacture. Company hereby grants to PPTI a
right of first offer to manufacture protein polymers contained in Products. In
the event Company determines to commercialize a Product, Company and PPTI shall
proceed as follows:

          (a) Company shall provide PPTI with notice of its intent to have a
Product manufactured and material terms and conditions of a potential supply
arrangement, including the terms set forth on Schedule B hereto (the "Noticed
                                              ----------
Manufacturing Services").

          (b) The parties shall negotiate in good faith to reach agreement on
all other terms and conditions relating to the provision of the Noticed
Manufacturing Services. In the event the parties are unable to reach agreement
within ** (the "Negotiation Period") after PPTI's receipt of notice from
Company, PPTI's option shall expire and Company shall be free to enter into
negotiations with any third party to provide the Noticed Manufacturing Services
upon terms not less favorable in the aggregate to Company than those specified
in the last written offer made by PPTI to Company. In determining whether any
third party's terms are less favorable in the aggregate to Company, only **
shall be considered.

          (c) Company may not enter into an agreement for the Noticed
Manufacturing Services on terms less favorable in the aggregate to Company
without first re-offering the Noticed Manufacturing Services on such terms to
PPTI, and PPTI shall have ** to accept such proposal (the "Re-Offer Period") .
In the event that PPTI does not accept within such ** period then Company shall
have the right to employ the third party to provide the Noticed Manufacturing
Services.

          (d) If Company has not entered into a definitive agreement with a
third party for the Noticed Manufacturing Services within ninety (90) days after
the later of the expiration of the Negotiation Period or the Re-Offer Period,
then the Company shall repeat the procedure set forth in this paragraph (c)
prior to entering in to any such definitive agreement.

          (e) At Company's request and expense, PPTI shall promptly establish,
qualify, procure any necessary permits and certifications for and otherwise
prepare for operation a back-up manufacturing site for the manufacture of any
protein polymers manufactured by PPTI pursuant to an agreement negotiated
pursuant to this Article 2.2. PPTI agrees that any contract between PPTI and a
                 -----------
third party for such back-up manufacturing site shall provide for **.

3.   ESCROW OF KNOW-HOW, ETC.
     -----------------------

          (a) Within thirty (30) days of the Effective Date, PPTI shall enter
into an escrow agreement with Company and an independent third-party escrow
agent mutually acceptable to the parties (the "Escrow Agent") in substantially
the form attached hereto as Schedule E (the "Escrow Agreement"). PPTI shall
                            ----------
cause to be deposited into escrow with the Escrow Agent copies of the Escrow
Materials in accordance with the terms of the Escrow Agreement.

** Material is confidential and has been omitted and filed separately with the
Securities and Exchange Commission.

                                        5

<PAGE>

          (b)  PPTI shall promptly and regularly update the Escrow Materials,
no less frequently than on an annual basis as required under the Escrow
Agreement. Company, at its own expense, may designate a neutral third party who
shall audit the Escrow Materials for purposes of determining whether PPTI has
fulfilled its deposit obligations and whether the Escrow Materials provide
sufficient Know-How for Company to manufacture protein polymers in the manner
contemplated under this Agreement, the Supply Agreement or any agreement
contemplated by the Supply Agreement. PPTI shall promptly correct any deficiency
disclosed by the audit. Furthermore, if the audit discloses a material
discrepancy, PPTI shall reimburse Company for the cost of the audit.

4.   PAYMENTS TO PPTI.
     ----------------

     4.1  License Fees. Upon execution and delivery of this Agreement, Company
          ------------
shall deliver to PPTI One Million (1,000,000) shares of the Company's common
stock pursuant to the Purchase Agreement.

     4.2  Royalties.
          ---------

          (a)  Subject to the provisions of this Agreement, Company shall pay
PPTI, within forty-five (45) days after the close of each Calendar Quarter
throughout the Royalty Term, a royalty equal to a percentage of Net Sales of
Products for the Calendar Quarter (or part thereof in the case of the first or
last Calendar Quarter for which a royalty is payable if not a full quarter) then
ended, as more fully set forth on Schedule C hereto; provided, however, that
                                  ----------
Company shall have no obligation to make any royalty payments hereunder until
the date (the "Royalty Term Commencement Date") that **. Notwithstanding
anything else in this Agreement, with respect to any sales of Product (i) in any
country in which there is not at least one Valid Claim, (ii) in any country in
which there is a competing product sold for the same or similar indication as
such Product and (iii) the sale of such Product would violate any Valid Claim
for any Patent if the sale had taken place in any other country, then the
applicable royalty percentage for sales of such Product in such country shall be
** of Net Sales.

          (b)  In the event any Product or Products are sold pursuant to a
sales agreement, marketing agreement, distribution agreement or similar
arrangement to which the Company is a party with any entity ("Net Distributor
Revenue"), Company shall pay PPTI, within forty-five (45) days after the close
of each Calendar Quarter, the royalty specified in Article 4.2(a) applied to the
                                                   --------------
Company's share or interest in the Product or Product-related revenue from said
entity's sale of Products; provided, however, that in no case shall Company have
any obligation to pay any amounts to PPTI under this Section 4.2(b) for the sale
of Products by Company to any other entities.

          (c)  All payments under this Agreement shall be made without
deduction of any taxes, charges, or duties except for such taxes, charges or
duties which are required under any applicable laws to be deducted. Any tax
deducted by Company or any Affiliate of Company under the laws of any foreign
country for the account of PPTI shall be promptly paid to the proper
governmental authority, and Company or its Affiliates shall furnish PPTI with
proof of payment of such tax together with official or other appropriate
evidence issued by the appropriate governmental authority sufficient to enable
PPTI to document claim for income tax

** Material is confidential and has been omitted and filed separately with the
Securities and Exchange Commission.

                                        6

<PAGE>

credit in respect to any sum so deducted. Any such tax required to be withheld
shall be an expense of and borne solely by PPTI.

          (d)  Company shall keep accurate books and records of all payments
due to PPTI for a period of three (3) years from the applicable payment period.
Said books of account shall be kept at Company's principal place of business or
the principal place of business of an appropriate Affiliate to which this
Agreement relates.

          (e)  PPTI shall have the right to nominate an independent accountant
acceptable to and approved by Company (which approval shall not be unreasonably
withheld) who shall have access to Company's records on reasonable notice during
reasonable business hours for the purpose of verifying, at PPTI's expense
(except as provided below), the royalty and Sublicense Payments payable as
provided for in this Agreement for the preceding year, but this right may not be
exercised more than once in any year. PPTI shall solicit or receive only
information relating to the accuracy of the royalty report and the royalty
payments made. Any underpayment or overpayment of royalty or Sublicense Payments
shall be paid within thirty (30) days of the delivery of a written accountants
report to Company and PPTI. Any overpayment of royalty or Sublicense Payments
shall be credited to the next royalty payment due from Company. If no further
royalty payments will be due then a refund will be made within thirty (30) days
of the audit. If the accountant's report shows an underpayment of royalties of
five percent (5%) or more, Company shall reimburse PPTI for all cost and expense
of the accountant's report.

          (f)  Company shall deliver to PPTI written reports of Net Sales, Net
Distributor Revenue and Sublicense Payments during the preceding Calendar
Quarter on or before the forty-fifty (45th) day following the end of each
Calendar Quarter. Such reports shall include a calculation of the earned royalty
due and shall be accompanied by the monies due. If no earned royalties are due,
then Company shall indicate such on its written report.

     4.3  Sublicense Fees.
          ---------------

          (a)  Company shall pay to PPTI an amount (the "Sublicense Payment")
equal to a percentage of any Sublicense Fees received by Company during the term
of this Agreement. Such percentage shall be based upon **

          (b)  In the event Company sublicenses rights under the License to
more than one Product to a third party pursuant to a single agreement, **.

          (c)  Company shall pay Sublicense Payments within forty-five (45)
days after receipt by Company of upfront or milestone payments and forty-five
(45) days after the end of the Calendar Quarter for any other Sublicense
Payments.

          (d)  Notwithstanding anything else, any Sublicense Payment for each
Product for any Calendar Quarter shall not exceed **.

          (e) Subject to Article 4.3(d) above, any Sublicense Payment based on a
                         --------------
sublicensee's sales of each Product for any Calendar Quarter shall be greater
than **.

** Material is confidential and has been omitted and filed separately with the
Securities and Exchange Commission.

                                        7

<PAGE>

          (f)  Notwithstanding any of the foregoing, any amounts paid by Company
under this Article 4.3 that are based upon up-front or milestone Sublicense Fees
           -----------
with respect to a sublicensee shall be carried forward as a credit against any
Sublicense Payments based upon sales of the Products by such sublicensee.

          (g)  For the purpose of clarity, Schedule F contains examples of the
                                           ----------
calculation of Sublicense Payments under this Article 4.3.
                                              -----------

5.   CONFIDENTIALITY.
     ---------------

     5.1  Subject to Article 5.3 and the terms of the Escrow Agreement, during
                     -----------
the term of this Agreement and for a period of ** thereafter, each party shall
maintain in confidence and shall not disclose to any third party any know-how,
trade secrets, business or technical information or other information
("Confidential Information") received from the other party relating to any
Product, and shall not use the other party's Confidential Information except for
the purposes of this Agreement without the prior written consent of such other
party. These confidentiality and non-use obligations shall not apply to any
Confidential Information that the receiving party can demonstrate:

          (a)  at the time of disclosure to the receiving party was, or
thereafter becomes, a part of the public domain through no fault of the
receiving party, its Affiliates, distributors or sub-licensees;

          (b) was subsequently lawfully disclosed to the receiving party by a
third party not under an obligation of confidentiality with or through the
disclosing party;

          (c) was in the lawful possession of the receiving party prior to
disclosure by the disclosing party; or

          (d) is required to be disclosed by judicial or administrative order
provided that notice is given to the disclosing party and the disclosing party
has an opportunity to seek a protective order, and further provided, that
disclosure is limited to compliance with the judicial or administrative order.

     5.2  During the term of this Agreement, each party shall take all
reasonable steps to:

          (a) prevent any disclosure in breach of Article 5.1 of Confidential
                                                  -----------
Information of the other which would be materially prejudicial to the interests
of the other party;

          (b) limit the disclosure of information to such of its Affiliates,
distributors and sub-licensees and their respective employees as require the
information for the purposes of this Agreement; and

          (c) procure that the persons referred to in paragraph (b) of this
Article 5.2 enter into appropriate confidentiality agreements.
-----------

     5.3  Notwithstanding the foregoing provisions of this Article, the
parties and their Affiliates, distributors and sub-licensees shall be entitled
to disclose Confidential Information of

** Material is confidential and has been omitted and filed separately with the
Securities and Exchange Commission.

                                        8

<PAGE>

the other party which would otherwise be protected by the provisions of Article
                                                                        -------
5.1 to actual or potential customers for any Product in so far as such
---
disclosure is reasonably necessary to commercialize such Product.

     5.4  Immediately upon the expiration or other termination of this
Agreement, Company shall return to PPTI all of the information regarding the
Know-How and all cell cultures and DNA provided by PPTI to Company ("Biological
Embodiments"), and all copies thereof (including summaries and notes thereof),
in its possession or control, except that one copy of such information (but not
Biological Embodiments) may be retained by Company's counsel under seal to
evidence compliance with this Agreement.

6.   INDEMNIFICATION.
     ---------------

     6.1 By Company. Company shall indemnify, defend and hold PPTI, its
         ----------
Affiliates, and the officers, directors and employees of PPTI and its Affiliates
harmless from and against any and all liabilities, damages, loss, cost or
expense (including reasonable attorneys' fees) resulting from third party claims
or suits brought against PPTI or its Affiliates which arise out of (i) Company's
breach of any of its duties or obligations under this Agreement, (ii) from any
willful misconduct or negligent acts or omissions of Company, its Affiliates,
distributors or employees in the manufacture, labeling, storage, transport,
distribution or commercialization of Product or (iii) a claim of intellectual
property infringement caused by the specific manner of use of a Product sold by
Company, or its Affiliates, sub-licensees or distributors.

     6.2 By PPTI. PPTI shall indemnify, defend and hold Company, its Affiliates,
         -------
distributors and sub-licensees harmless against all liabilities, damages, loss,
cost or expense (including reasonable attorneys' fees) resulting from third
party claims and suits brought against them which arise out of (i) PPTI's breach
of any of its duties or obligations under this Agreement, (ii) any willful
misconduct or negligent acts or omissions of PPTI or its Affiliates, licensees
or employees in the manufacture, labeling, storage, transport, distribution or
commercialization of Product, (iii) any misappropriation of any trade secret or
trade secrets by PPTI in the acquisition or development of the Intellectual
Property, (iv) with respect to Products for which all or a portion was
manufactured by PPTI, any claim of infringement of composition of matter or
method of manufacture by such portion manufactured by PPTI, or (v) with respect
to Products not manufactured by PPTI, or portions of Products not manufactured
by PPTI, any claim of infringement of intellectual property rights relating to
**.

     6.3 Notice and Defense. Each party seeking indemnity ("Claimant") pursuant
         ------------------
to this Article shall promptly notify in writing the other ("Indemnitor") of any
claims or suits for which it seeks indemnification from the other party. The
Indemnitor shall promptly assume responsibility for the defense of the claim or
suit, including settlement negotiations and any legal proceedings which
Indemnitor shall handle at its sole discretion, and Claimant shall fully
cooperate in Indemnitor's handling and defense thereof. In no event shall a
Claimant make any payment on any claim or suit for which indemnity may be sought
without the prior written consent of the Indemnitor.

** Material is confidential and has been omitted and filed separately with the
Securities and Exchange Commission.

                                        9

<PAGE>

7.   LIMITED LIABILITY. NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT OR
     -----------------
OTHERWISE, NEITHER PARTY SHALL BE LIABLE OR OBLIGATED UNDER ANY SECTION OF THIS
AGREEMENT OR UNDER CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR
EQUITABLE THEORY FOR ANY SPECIAL, EXEMPLARY, INDIRECT, INCIDENTAL OR
CONSEQUENTIAL DAMAGES.

8.   OWNERSHIP.
     ---------

     8.1  Reserved Rights. PPTI retains all rights to the Intellectual Property
          ---------------
not expressly granted to Company pursuant to this Agreement.

     8.2  Ownership of Inventions.
          -----------------------

          (a)  As between the parties, all right, title and interest to any
inventions or discoveries ("Inventions") made by Company employees or agents
without inventive contribution by PPTI employees or agents and conceived or
first reduced to practice under this Agreement or the Supply Agreement shall
belong to Company. As between the parties, all right, title and interest to any
Inventions made by PPTI employees or agents without inventive contribution by
Company employees or agents and conceived or first reduced to practice under the
Supply Agreement ("PPTI Inventions") shall belong to PPTI. Right, title and
interest to any Inventions made jointly by employees or agents of PPTI and
Company shall **.

          (b)  PPTI hereby grants and agrees to grant to Company a nonexclusive,
royalty-bearing (in accordance with the royalties set forth in Schedule C),
                                                               ----------
perpetual, irrevocable, worldwide right and license to the PPTI Inventions
solely for applications within the Field.

          (c)  Each party hereby makes any assignments necessary to accomplish
the foregoing ownership provisions.

     8.3  Records. Each party shall require its employees or agents responsible
          -------
for conducting research in performance of this Agreement to keep contemporaneous
records of their results and findings in sufficient detail to document any
inventions of discoveries made by such employees and agents under this Agreement
in bound notebooks (that shall be reviewed and signed by a witness on a regular
basis).

9.   TERM AND TERMINATION.
     --------------------

     9.1  The term of this Agreement shall commence as of the date it is
executed and delivered by both parties, and, unless terminated earlier in
accordance with its terms, shall continue for the greater of twenty (20) years
from the Effective Date or the date upon which the last of the Patents expires.

     9.2  This Agreement may be terminated as follows:

          (a)  On or prior to the last day of the tenth full calendar month
after the Effective Date, PPTI may terminate this Agreement, upon one (1) month
prior written notice, in the event that Company shall fail to make the Minimum
Payment (as defined in the Supply

** Material is confidential and has been omitted and filed separately with the
Securities and Exchange Commission.

                                       10

<PAGE>

Agreement) due to PPTI during the Initial Term (as defined in the Supply
Agreement) under the Supply Agreement; provided however, that PPTI may not
terminate this Agreement due to Company's failure to make such payments
according to Section 6(d)(iii) of the Supply Agreement.

          (b)  Starting on the first day of the eleventh full calendar month
following the Effective Date, PPTI may terminate this Agreement, upon ** prior
written notice, in the event that Company (x) does not receive at least $2
million in cash within one year from the Effective Date, (y) abandons all
reasonable efforts to obtain financing through the sale of its preferred stock,
or (z) abandons efforts to commercialize Products, by giving notice of its
intent to terminate and stating the grounds therefor.

          (c)  In the event of the material breach by either party of any
material provision of this Agreement, which breach is not cured within ** after
written notice of such breach is given by the non-breaching party (if such
breach is not reasonable curable within ** and the breaching party has been and
continues using best efforts to effect a cure, such period may be extended as
necessary for up to an additional **), then the non-breaching party may, in
addition to any other remedies which may be available at law or in equity,
terminate this Agreement effective ** after a second written notice thereof to
the breaching party.

          (d)  On or prior to the last day of the fifth full calendar month
after the Effective Date, Company may terminate this Agreement, upon one (1)
month prior written notice, in the event that (x) no Product has been
demonstrated to meet specific bio-mechanical standards set forth on Schedule D
                                                                    ----------
hereto, (y) upon receipt by Company of a written opinion from patent counsel
that commercialization of Product for disk augmentation would infringe claims of
a third party patent that would likely be held as valid, provided that patent
counsel to PPTI, in good faith and upon reasonable analysis concurs with such
opinion, or (z) PPTI does not receive, subsequent to March 1, 2001 and on or
prior to April 15, 2001, at least One Million US dollars ($1,000,000) in cash,
excluding any payments from Company to PPTI.

          (e)  Starting on the first day of the sixth full calendar month
following the Effective Date, Company may terminate this Agreement for any
reason upon ** prior written notice.

          (f)  In the event (i) PPTI terminates the Supply Agreement due to a
material breach by Company of its payment obligations under Section 6 of the
Supply Agreement, (ii) of a material breach by Company of Section 1 of the
Purchase Agreement that is not cured within ** notice thereof or (iii) of a
material breach by Company of Section 1(a) or 1(b) of the Voting Agreement that
is not cured within ** notice thereof, then PPTI shall have the right to
terminate this Agreement effectively immediately upon notice thereof.

     9.3   Effects of Termination or Expiration. Subject to Articles 9.2 and 10
           ------------------------------------             ------------     --
upon the expiration or termination of this Agreement, the obligations and rights
of PPTI and Company hereunder shall immediately terminate; provided that
following such expiration or termination Company, its Affiliates, distributors
and sub-licensees shall continue to have the right to sell, for a reasonable
period not to exceed ninety (90) days following the date of termination or
expiration, any Product then held in its inventory at not less than 75% of its
then usual and

** Material is confidential and has been omitted and filed separately with the
   Securities and Exchange Commission.

                                       11

<PAGE>

customary sales prices; and provided further that notwithstanding such
termination or expiration, Company shall pay to PPTI any royalties due to it
through and including the sale of such inventory Product.

10.  RIGHTS UPON TERMINATION.
     -----------------------

     10.1  Subject to Article 9, the termination or expiration of this Agreement
                      ---------
shall not relieve and release either party from its obligations to make any
other payment which may be owing to the other party under the terms of this
Agreement or from any other liability which either may have to the other arising
out of this Agreement or the breach of this Agreement.

     10.2  All provisions of this Agreement which in order to give effect to
their meaning need to survive its termination or expiration shall remain in full
force and effect thereafter, including without limitation Articles 1, 5-8, 9.3,
                                                          ---------------------
10, 13-17, and 19-22.
--------------------

11.  PATENTS.
     -------

     11.1  (a)  PPTI agrees that it shall, at its sole expense, diligently
prosecute (and thereafter maintain) all patents applications for Patents
existing as of the Effective Date in ** and, when reasonable under the
circumstances or required by a Patent Office because more than one invention is
claimed in an application, to file and prosecute additional patent applications,
re-examinations, reissues or the like covering patentable technology disclosed
in the Patents in **.

           (b)  PPTI shall have the duty and responsibility to pay when due for
payment all taxes, maintenance fees and annuities on the Patents and to maintain
in force all patents within the Patents for the full terms thereof.

           (c)  PPTI shall, within thirty (30) days of mailing or receipt,
provide Company with copies of all future filed patent applications relating to
the Patents and, upon request, all correspondence from and to patent offices
worldwide relating to both the Patents and future filed patent applications,
re-examinations, reissues or the like. PPTI shall provide Company with an update
on the status of the Patents on at least an annual basis and shall fully
consider any suggestions of Company with respect to the Patents.

           (d)  In the event PPTI elects not to prosecute or maintain any
Patents existing as of the Effective Date in any countries other than ** where
it is possible to do so, PPTI shall notify Company (such notice to specify
clearly the countries in respect of which it is not going to take such actions)
promptly following any such decision, and in any event no later than two (2)
months (except with regard to actions due **) before the expiration of any
material time period in respect of such actions, and Company shall, in its sole
discretion, have the right to elect to assume the prosecution and maintenance of
such patent application and patent on behalf of PPTI in respect of any such
actions (including for the avoidance of doubt filing any applicable patent
applications and prosecuting to grant any applicable patents and thereafter
maintaining such patents) and PPTI shall cooperate fully and promptly with
Company in the taking of any such actions by it.

           (e)  PPTI may with reasonable justification and having fully
considered Company's input decide in good faith not to file patent
application(s) on inventions or

** Material is confidential and has been omitted and filed separately with the
   Securities and Exchange Commission.

                                       12

<PAGE>

discoveries made by PPTI employees or agents outside of the Supply Agreement.
However, in the event PPTI decides to file a patent application for such
invention or discovery, it shall file a patent application in **, and in the
event PPTI also decides to file a patent application outside of **, it shall
also file patent applications covering **. In the event PPTI files any patent
application with respect to such inventions or discoveries, then, subject to
Article 11.3, PPTI shall be responsible for the obligations under Article 11.1
------------                                                      ------------
with respect to such patent application and any patent issuing therefrom.

     11.2

           (a)  In the event PPTI decides to file a patent application for a
PPTI Invention, it shall file a patent application for such PPTI Invention in
**, and in the event PPTI also decides to file a patent application for a PPTI
Invention outside of **, it shall also file patent applications covering **. In
the event PPTI files any patent application with respect to PPTI Inventions,
then, subject to Article 11.3, PPTI shall be responsible for the obligations
                 ------------
under Article 11.1 with respect to such patent application and any patent
      ------------
issuing therefrom.

           (b)  If PPTI decides not to file a patent application with respect to
the PPTI Inventions in any country, then it shall notify Company (such notice to
specify clearly the countries in respect of which it is not going to take such
actions) promptly following any such decision, and in any event no later than
two (2) months before the expiration of any material time period in respect of
such actions, and Company shall, in its sole discretion, have the right to elect
to assume the prosecution of such patent application on behalf of PPTI in
respect of any such actions (including for the avoidance of doubt filing any
applicable patent applications and prosecuting to grant any applicable patents
and thereafter maintaining such patents) and PPTI shall cooperate fully and
promptly with Company in the taking of any such actions by it.

     11.3  (a)  If PPTI does not comply with any of the actions required to be
taken by it under Article 11.1(a), 11.1(b) or 11.1(e) with respect to any patent
                  -----------------------------------
or patent application, Company shall, in its sole discretion, have the right to
elect to assume the prosecution and maintenance of such patent application or
patent on behalf of PPTI in respect of any such actions (including for the
avoidance of doubt filing any applicable patent applications and prosecuting to
grant any applicable patents and thereafter maintaining such patents) and PPTI
shall co-operate fully and promptly with Company in the taking of any such
actions by it.

           (b)  If Company elects to assume the prosecution or filing activities
under Article 11.1(d), 11.2(b) or 11.3(a), it shall pay the costs and expenses
      -----------------------------------
of taking such actions and, notwithstanding anything in Articles 4.2 and 4.3 to
                                                        -----------------------
the contrary, Company's obligation to pay a royalty to PPTI for sales in such
country under Article 4 shall be reduced by ** until Company shall have
              ---------
recovered all costs and expenses associated with filings, prosecuting, issuing
and maintaining said patent applications or patent(s).

           (c)  Company shall be entitled to deduct all costs and expenses as
aforesaid with respect to the Patents and patent applications on PPTI Inventions
in ** from any sums payable to PPTI under this Agreement until they have been
reimbursed in full.

** Material is confidential and has been omitted and filed separately with the
   Securities and Exchange Commission.

                                       13

<PAGE>

     11.4  The parties agree to use commercially reasonable efforts to cooperate
in order to avoid loss of any rights which may otherwise be available to the
parties under the U.S. Drug Price Competition and Patent Term Restoration Act of
1984, the Supplementary Certificate of Protection of the Member States of the
European Common Market and other similar measures in any other country. However,
such cooperation shall not interfere with PPTI taking actions to protect other
products or Intellectual Property rights.

     11.5  Cooperation. PPTI and Company will cooperate, and shall cause its
           -----------
employees, agents and investigators, as the case may be, in a timely manner to
prepare, review and execute patent applications and all such further papers, as
may be necessary to enable the parties or the party pursuing any patent
application to protect any Inventions by patent or other patents under this
Article 11 or Article 8 in any and all countries and to vest title to said
patent application(s) and patent(s) and assist in Patent Office proceedings. If
one party determines to prosecute patent applications regarding an invention
owned ** by the parties under Article 8.2(a) and the other party does not desire
                              --------------
to do so, the party that does not undertake such prosecution activities shall
pay to the other party a fee equal to ** of the net sales derived from sales of
products covered in whole in part by any patent issuing upon such joint
invention beginning upon the issuance of such patent(s).

12.  INFRINGEMENT.
     ------------

     12.1

           (a)  If a third party asserts that a patent or other right owned by
it is infringed by the manufacture, import, marketing, use, sale, offer for sale
and/or supply of any Product, the party first obtaining knowledge of such claim
shall promptly provide the other party notice of such claim and the related
facts in reasonable detail. Notwithstanding any provision in this Agreement to
the contrary, except subject to indemnification obligations of PPTI, the defense
of any such claim (including without limitation, the institution and prosecution
of any counterclaims thereto) shall be controlled by Company. However, nothing
in this Article 12.1 will prevent PPTI from engaging its own counsel in any such
matter if there shall exist a bona fide conflict between the rights and interest
of PPTI and Company.

           (b)  Without its prior written consent, PPTI will not be responsible
for or bound by any compromise made by Company. Without its prior written
consent, Company will not be responsible for or bound by any compromise made by
PPTI.

           (c)  If it is necessary to obtain a license from such third party,
PPTI and Company in negotiating such a license shall, to the extent practicable,
use their reasonable efforts to minimize the license fees and/or royalty payable
to such third party.

     12.2

           (a)  In the event that there is infringement or misappropriation of
any Intellectual Property by a third party, PPTI and Company shall notify each
other in writing to that effect immediately upon becoming aware of the same,
including if practicable with said

** Material is confidential and has been omitted and filed separately with the
   Securities and Exchange Commission.

                                       14

<PAGE>

written notice evidence establishing a case of infringement or misappropriation
by such third party.

           (b)  Company shall have the right, in its sole discretion, but not
the obligation to bring such suit at its own expense and in its own name, if
possible, or jointly in its name and in the name of PPTI or if necessary in
PPTI's sole name if such infringement involves the use of Intellectual Property
in the Field.

           (c)  Company shall bear all the expenses of any suit brought by it
and shall retain all damages or other monies awarded or received in settlement
of such suit; provided, however, that at Company's option exercised by notice in
writing to PPTI before it commences such suit PPTI may contribute to the
expenses of any such suit and, in such event, Company and PPTI shall share
proportionately to their respective contributions all damages or other monies
awarded or received in settlement of such suit.

           (d)  PPTI will cooperate with Company in any such suit and shall have
the right to consult with Company and, if it elects pursuant to the proviso to
paragraph (c) of this Article, to be separately represented by its counsel at
its own expense.

13.  ARBITRATION OF DISPUTES.
     -----------------------

     13.1  Excepting only actions and claims relating to actions commenced by a
third party against PPTI or Company (including, without limitation, for injuries
caused by a Product or in respect to a trademark or patent infringement claim),
any controversy or claim arising out of or relating to the terms and conditions
of this Agreement, or the decision to agree upon these terms, or the breach
thereof, including questions of validity, infringement, or termination hereof,
shall be settled exclusively by arbitration in accordance with the rules of the
American Arbitration Association. If such controversy or claim relates to patent
validity or infringement, then the Patent Arbitration Rules of the AAA shall
apply; otherwise the International Arbitration Rules of the AAA shall apply.
Notwithstanding the foregoing to the contrary or in the arbitration rules
invoked or in this Article 13, the parties retain the right to request a
                   ----------
judicial authority to invoke interim measures of protection, and such request
shall not be deemed incompatible with this agreement to arbitrate or a waiver of
the right to arbitrate.

     13.2  There shall be one (1) arbitrator to be mutually agreed upon by the
parties and to be selected from the Regional Panel of Distinguished Neutrals. If
the parties are unable to agree upon such an arbitrator who is willing to serve
within ten (10) days of receipt of the demand by the other party, the parties
shall within three (3) days select one of the five largest international public
accounting firms (excluding those providing services to the parties) and engage
the managing partner or senior officer of its County office located in the
county containing the principal place of business of the party who did not
initiate the arbitration to designate a partner of such firm to serve as the
arbitrator. Failing that, then the AAA shall appoint an arbitrator willing to
serve from the Regional Panel of Distinguished Neutrals, or if no such panel
exists, then from an appropriate AAA panel. It shall be the duty of the
arbitrator to set dates for preparation and hearing of any dispute and to
expedite the resolution of such dispute.

                                       15

<PAGE>

     13.3  (a)  The arbitration shall be held in the city in which the
principal place of business of the party who did not initiate the arbitration is
located and the arbitrator shall apply the substantive law of California except
that the interpretation and enforcement of this arbitration provision shall be
governed by the Federal Arbitration Act.

           (b)  The arbitrator shall permit and facilitate discovery, which will
be conducted in accordance with the Federal Rules of Civil Procedure, taking
into account the needs of the parties and the desirability of making discovery
expeditious and cost-effective.

           (c)  The arbitrator will set a discovery schedule with which the
parties will comply and attend depositions if requested by either party.

           (d)  The arbitrator will entertain such presentation of sworn
testimony or evidence, written briefs and/or oral argument as the parties may
wish to present, but no testimony or exhibits will be admissible unless the
adverse party was afforded an opportunity to examine such witness and to inspect
and copy such exhibits during the pre-hearing discovery phase.

           (e)  The arbitrator shall among his other powers and authorities,
have the power and authority to award interim or preliminary relief.

           (f)  The arbitrator shall not be empowered to award either party
exemplary or punitive damages or any enhanced damages for willful infringement
and the parties shall be deemed to have waived any right to such damages.

           (g)  A qualified court reporter will record and transcribe the
proceeding.

           (h)  The decision of the arbitrator will be in writing and judgment
upon the award by the arbitrator may be entered in any court having jurisdiction
thereof.

           (i)  Prompt handling and disposal of the issue is important.
Accordingly, the arbitrator is instructed to assume adequate managerial
initiative and control over discovery and other aspects of the proceeding to
schedule discovery and other activities for substantially continuous work,
thereby expediting the arbitration as much as is deemed reasonable to him, but
in all events to effect a final award within 365 days of the arbitrator's
selection or appointment and within 20 days of the close of evidence.

           (j)  The proceedings shall be confidential and the arbitrator shall
issue appropriate protective orders to safeguard both parties' confidential
information.

           (k)  The fees of the arbitrator and the AAA shall be paid as
designated by the arbitrator or, if he shall not so designate, they shall be
split equally between the parties.

14.  NOTICES.
     -------

     14.1  Notices hereunder shall be in writing and shall be deemed to have
been duly given if personally delivered or when sent by facsimile or other
telegraphic means. Such notices shall be effective upon receipt, if by personal
delivery, or if by facsimile, on the date of the

                                       16

<PAGE>

confirmation of "ok" transmission. Addresses and persons to be notified may be
changed by either party by giving written notice thereof to the other party.

           For Company:

                 Spine Wave, Inc.
                 12230 El Camino Real, Suite 300
                 San Diego, California 92130
                 Attention: David Coats
                 Fax: (858) 350-7951

           With a copy to:

                 Brobeck, Phleger & Harrison LLP
                 12390 El Camino Real
                 San Diego, California 92130
                 Attention: Faye H. Russell, Esq.
                 Fax: (858) 350-7951

           For PPTI:

                 Protein Polymer Technologies, Inc.
                 10655 Sorrento Valley Road
                 San Diego, California 92121
                 Attention: President
                 Fax: (858) 558-6477

           With a copy to:

                 Piper Marbury Rudnick & Wolfe
                 203 North LaSalle Street, Suite 1800
                 Chicago, Illinois 60601
                 Attention: John H. Heuberger, Esq.
                 Fax: (312) 630-5322

15.  FORCE MAJEURE.
     -------------

     15.1  (a)   Subject to compliance with paragraph (b) of this Article 15.1
                                                                  ------------
any delays in or failure of performance by either party under this Agreement
shall not be considered a breach of this Agreement if and to the extent caused
by any occurrences beyond the reasonable control of the party affected,
including but not limited to: acts of God; acts, regulations or laws of any
government; strikes or other concerted acts of workers; fires; floods;
explosions; riots; wars; rebellion; embargo; and sabotage; and any time for
performance hereunder shall be extended by the actual time of delay caused by
such occurrence.

                                       17

<PAGE>

           (b)  Any party affected by such force majeure who wishes to rely on
the provisions of paragraph (a) of this Article shall as soon as reasonably
practicable give written notice to the other party specifying the matters
constituting force majeure together with such evidence thereof as it can
reasonable give and specifying the period for which it is estimated that the
such delay will continue.

16.  SAVINGS PROVISION.
     -----------------

     16.1  The invalidity of any provision of this Agreement shall not impair
the validity of any other provision; and any provision hereof which might
otherwise be invalid or contravene any applicable law shall hereby be deemed to
be amended to the extent necessary to remove the cause of such invalidity and to
the extent practicable to continue the intent of such provision and of this
Agreement, and such provision, as so amended, shall remain in full force and
effect as a part hereof.

17.  RELATIONSHIP OF PARTIES.
     -----------------------

     17.1  Each party shall act as an independent contractor in carrying out its
obligations under this Agreement. Nothing contained in this Agreement shall be
construed to imply a joint venture, partnership or principal-agent relationship
between the parties, and neither party by virtue of this Agreement shall have
the right, power or authority to act or create any obligation, express or
implied, on behalf of the other party. This Agreement shall not be construed to
create rights, express or implied, on behalf of or for the use of any party
aside from Company and PPTI, and neither party shall be obligated, separately or
jointly, to any third parties by virtue of this Agreement.

18.  WARRANTIES.
     ----------

     18.1  Company warrants that it shall use its reasonable and diligent
efforts to comply with all laws applicable to the purchase, storage, transport,
labeling, distribution or commercialization by it of the Product, shall comply
with the U.S. Export Administration laws and regulations and shall not export or
re-export any technical data or Intellectual Property, or the direct products of
such technical data or Intellectual Property, or Products to any prohibited
country listed in the U.S. Export Administration Regulations unless properly
authorized to do so by the U.S. government.

     18.2  PPTI represents and warrants to Company that the following statements
are true and accurate in all material respects as follows:

           (a)  It has sufficient right and title to and ownership of, and is
sufficiently free and clear of all liens, claims and encumbrances of any nature
on, the Intellectual Property to grant to Company the various rights and
licenses granted to Company under this Agreement;

           (b)  It has not done, will not do nor agree to do during the term of
this Agreement, any of the following things if to do so would be materially
inconsistent with the exercise by Company of the rights granted to it under this
Agreement, including assign,

                                       18

<PAGE>

mortgage, hypothecate, or otherwise transfer any of the Intellectual Property,
including without limitation, the Patents, or any of its rights or obligations
under this Agreement;

           (c)  Except for standard rights granted to the United States
government in connection with Small Business Innovation Research grants, it is
not aware that any third party owns any rights in the Intellectual Property that
would adversely affect any of the rights and licenses granted to Company under
this Agreement;

           (d)  Without conducting any investigation, it is not aware that any
third party owns any rights which would be infringed by the use of the Products
for ** in accordance with provisions of this Agreement.

           (e)  In the event Company consults with PPTI regarding future
intended uses of the Products, PPTI shall, without any obligation to conduct any
investigation, in good faith disclose to Company any third party rights of which
it is aware which might be infringed by such uses of the Products.

           (f)  It is duly authorized and empowered to enter into and perform
this Agreement; and the execution and performance of this Agreement by PPTI does
not and will not conflict with or violate any contract, agreement, indenture,
mortgage, instrument, writ, judgment, or order of any court, arbiter or
governmental or quasi-governmental body to which PPTI is a party or by which
PPTI is bound.

19.  INTEGRATION AND CONFLICT.
     ------------------------

     19.1  (a)  It is the mutual desire and intent of the parties to provide
certainty as to their future rights and remedies against each other by defining
the extent of their mutual undertakings provided herein. This Agreement and the
related Supply Agreement, Escrow Agreement, the Voting Agreement and Purchase
Agreement:

                (i)  constitute the entire agreement and understanding between
the parties with respect to the subject matter contained herein, and there are
no promises, representations, conditions, provisions or terms related thereto
other than as set forth in this Agreement and the related Supply Agreement,
Escrow Agreement, Voting Agreement and Purchase Agreement; and

                (ii) supersede all previous understandings and agreements, and
representations between the parties, whether written or oral, relating to the
subject matter.

           (b)  The parties may from time to time during the term of this
Agreement modify any of its provisions by mutual agreement in writing.

           (c)  The parties agree that each has had the opportunity to be
represented by counsel of it choosing including the negotiations that preceded
this Agreement.

           (d)  In the event of any conflict between the provisions of this
Agreement and the Supply Agreement, unless expressly stated in this Agreement,
the provisions of this Agreement shall prevail.

**Material is confidential and has been omitted and filed separately with the
  Securities and Exchange Commission.

                                       19

<PAGE>

20.  GOVERNING LAW.
     -------------

     20.1  This Agreement shall be construed and the rights of the parties shall
be determined in accordance with the substantive laws of the State of
California, without regard to its conflict of laws principles, except that the
Arbitration provisions contained herein shall be governed as stated in Article
                                                                       -------
13.
--

21.  ASSIGNMENT.
     ----------

     21.1  Neither party shall assign or otherwise transfer this Agreement or
any part hereof (and any attempt to do so will be void) to any third party
without the prior written permission of the other party, except to an entity
that acquires all or substantially all of such party's assets or operations.

22.  BANKRUPTCY.
     ----------

     22.1  The parties hereto acknowledge and agree that it is their mutual
intention and agreement that should PPTI become a debtor in case under title 11
of the United States Code (the "Bankruptcy Code"), then the Company shall be
entitled to all the benefits accorded a licensee under Bankruptcy Code Section
365(n). Furthermore, it is hereby acknowledged and agreed that this Agreement
shall be "such contract" as that phrase is used in Section 365(n) and that:

           (a)  the Escrow Agreement, the Supply Agreement, any subsequent
supply agreement which may be entered into by the parties, and any other
agreement executed pursuant to Supply Agreement or in order to allow the Company
to exploit the Intellectual Property shall each be considered an "agreement
supplementary to such contract" as that phrase is used in said Section 365(n);

           (b)  in addition to any rights specifically set forth in the Escrow
Agreement, all of "Escrow Materials" shall be included within the definition of
"any embodiment of such intellectual property" as such phrase is used in said
Section 365(n), along with any other embodiment of the Intellectual Property;

           (c)  upon rejection of this Agreement, the Company shall be deemed to
have requested of PPTI as debtor in possession (or of PPTI's trustee, if any)
that PPTI as debtor in possession or such trustee (A) immediately provide and
deliver to the Company or any Affiliate as the Company may subsequently
designate in writing, all embodiments of the Intellectual Property, including
without limitation, all of the Escrow Materials, without further notice or
seeking relief from the automatic stay or other leave from any court; and (B)
not interfere with the rights of the Company, its Affiliates, and/or any
sub-licensee under this Agreement, the Escrow Agreement, any supply agreement,
or any other agreement supplementary to the Supply Agreement, including any
right to obtain Intellectual Property, the Escrow Materials, or any embodiment
of the Intellectual Property from another entity (such as the Escrow Agent); and

           (d)  Unless and until PPTI as debtor in possession or PPTI's trustee
(if any) rejects this agreement or any agreement supplementary to this
Agreement, then upon the written request of the Company, and pursuant to
Bankruptcy Code Section 365(n)(4), PPTI as debtor in possession or PPTI's
trustee (if any) shall: (A) at the Company's option either perform this

                                       20

<PAGE>

Agreement, or provide and deliver to the Company all embodiments of the
Intellectual Property, including without limitation, all the Escrow Materials,
held by either PPTI as debtor in possession or PPTI's trustee (if any); and (B)
not interfere with the rights of the Company, its Affiliates, and/or any
sub-licensee under this Agreement, the Escrow Agreement, the Supply Agreement,
or any other agreement supplementary to the Supply Agreement, including any
right to obtain rights to or embodiments of the Intellectual Property, including
without limitation, the Escrow Materials, or any embodiment of the Intellectual
Property from another entity (such as the Escrow Agent).

23.  NONSOLICITATION.
     ---------------

     During the term of this Agreement, neither party will solicit any employee
to leave the employ of the other; the foregoing does not prohibit mass media
advertising or retained or contingency searches not specifically directed
towards employees of a party.

24.  PRESS RELEASES.
     --------------

     Except as required by law or as expressly set forth herein, neither party
shall make any public statement, press release or other announcement relating to
the terms or existence of this Agreement, or the business relationship of the
parties, without the prior written consent of the other party.

                                       21

<PAGE>

         IN WITNESS WHEREOF, PPTI and Company have caused this Agreement to be
executed as of the date first written above.

PROTEIN POLYMER TECHNOLOGIES, INC.             SPINE WAVE, INC.

By:_______________________________________     By:______________________________
     J. Thomas Parmeter                           David Coats
     President and Chief Executive Officer        President and Chief Executive
                                                  Officer

                     [SIGNATURE PAGE TO LICENSE AGREEMENT]

<PAGE>

                                   SCHEDULE A

                               Schedule of Patents
                               -------------------

<TABLE>
<CAPTION>
U.S. Patent No.                           Title                               Issue Date
<S>                <C>                                                        <C>
5,235,041          Purification of structurally ordered recombinant protein   Aug 10, 93
                   polymers

5,243,038          Construction of synthetic DNA and its use in large         Sep 7, 93
                   polypeptide synthesis

5,496,712          High molecular weight collagen-like protein polymers       Mar 5, 96

5,514,581          Functional recombinantly prepared synthetic protein        May 7, 96
                   polymer

5,606,019          Synthetic proteins as implantables                         Feb 25, 97

5,641,648          Methods for preparing synthetic repetitive DNA             Jun 24, 97

5,723,588          Protein-enriched thermoplastics                            Mar 3, 98

5,760,004          Chemical modification of repetitive polymers to enhance    Jun 2, 98
                   water solubility

5,770,697          Peptides comprising repetitive units of amino acids        Jun 23, 98
                   and DNA sequences encoding the same

5,773,249          High molecular weight collagen-like protein polymers       Jun 30, 98

5,773,577          Products comprising substrates capable of enzymatic        Jun 30, 98
                   cross-linking

5,808,012          Protein-enriched thermoplastics                            Sep 15, 98

5,817,303          Bonding together tissue with adhesive containing           Oct 6, 98
                   polyfunctional crosslinking agent and protein polymer

5,830,713          Methods for preparing synthetic repetitive DNA             Nov 3, 98

6,015,474          Methods of using primer molecules for enhancing the       Jan 18, 00
                   mechanical performance of tissue adhesives and sealants

6,018,030          Peptides comprising repetitive units of amino acids        Jan 25, 00
                   and DNA sequences encoding the same

6,033,654          Bonding together tissue with adhesive containing           Mar 7, 00
                   polyfunctional crosslinking agent and protein polymer

6,034,220          Chemical modification of repetitive polymers to            Mar 7, 00
                   enhance water solubility

6,140,072          Functional recombinantly prepared synthetic protein        Oct 31, 00
                   polymer
</TABLE>

                                      A-1

<PAGE>

<TABLE>
<CAPTION>
U.S. Patent No.                                  Title                           Issue Date
<S>                 <C>                                                          <C>
6,184,348           Functional recombinantly prepared synthetic protein          Feb 6, 01
                    polymer

s/n 08/806,029      Synthetic Proteins for In Vivo Drug Delivery and Tissue      Pending
                    Augmentation

s/n 09/102,521      Methods of using primer molecules for enhancing the          Pending
                    mechanical performance of tissue adhesives and sealants

s/n 09/444,791      Novel Peptides comprising repetitive units of amino acids    Pending
                    and DNA sequences encoding the same

s/n 09/451,206      Tissue Adhesive Using Synthetic Crosslinking                 Pending
</TABLE>

                                      A-2

<PAGE>

                                   SCHEDULE B

                       MANUFACTURING TERMS AND CONDITIONS
                       ----------------------------------

1.   PPTI shall supply protein polymers to Company at a price equal to **.
     Thereafter, any reductions in PPTI's cost shall be ** between PPTI and
     Company as determined on an annual basis.

2.   Company shall have the right to retain an independent accountant approved
     by PPTI, which approval shall not be unreasonably withheld, who shall have
     access to PPTI's records on reasonable notice during reasonable business
     hours for the purpose of verifying, at Company's expense (except as
     provided below), PPTI's costs associated with manufacturing protein
     polymer(s) for the Company as provided for in this Article, but this right
     may not be exercised more than once in any year. Any overstatement or
     understatement of costs shall be credited to the next payment due by the
     Company and any remainder shall be promptly reimbursed to the Company. If
     the accountant's report shows an overstatement of costs of five percent
     (5%) or more, PPTI shall reimburse Company for all cost and expense of the
     accountant's report.

**  Material is confidential and has been omitted and filed separately with the
    Securities and Exchange Commission.

                                      B-1

<PAGE>

                                   SCHEDULE C

                              Schedule of Royalties
                              ---------------------

**

** Material is confidential and has been omitted and filed separately with the
   Securities and Exchange Commission.

                                      C-1

<PAGE>

                                   SCHEDULE D

                            Bio-mechanical Standards
                            ------------------------

**

** Material is confidential and has been omitted and filed separately with the
   Securities and Exchange Commission.

                                      D-1

<PAGE>

                                   SCHEDULE E

                            Form of Escrow Agreement
                            ------------------------

Filed separately under Exhibit 10.40 of the Registrant's Form 10-KSB for fiscal
year ended December 21, 2001.

                                      E-1

<PAGE>

                                   SCHEDULE F

                  Example of calculation of Sublicense Payments
                  ---------------------------------------------

**

** Material is confidential and has been omitted and filed separately with the
   Securities and Exchange Commission.

                                      F-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}]]